Cingulate Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2012

Location

KS US

Primary Industry

Biotechnology

About

Founded in 2012 and based in Kansas, US, Cingulate Therapeutics, Inc. operates as a biopharmaceutical company that develops medications for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The firm trades under the NASDAQ stock exchange under the ticker symbol CING. In February 2024, Cingulate Therapeutics, Inc. raised USD 7.5 million in a private placement by selling 3.75 million shares at USD 2 per share on the NASDAQ. The firm as of July 2024, is led by its co-founders, Shane J. Schaffer (Chairman and CEO) and Raul R. Silva (CSO). The clinical-stage biopharmaceutical company specializes in developing treatments for central nervous system disorders. With a focus on addressing the substantial market for ADHD and anxiety medications in the United States, Cingulate leverages its proprietary Precision Timed Release™ (PTR™) platform technology. This platform allows for the development of next-generation pharmaceuticals designed to enhance treatment outcomes by delivering precise doses over extended periods, minimizing side effects associated with traditional dosing regimens. Cingulate's pipeline includes CTX-1301 and CTX-1302 for ADHD, and CTX-2103 for anxiety.

Current Investors

Werth Family Investment Associates

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.cingulatetherapeutics.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.